These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 24312302)
21. Gene carriers and transfection systems used in the recombination of dendritic cells for effective cancer immunotherapy. Chen YZ; Yao XL; Tabata Y; Nakagawa S; Gao JQ Clin Dev Immunol; 2010; 2010():565643. PubMed ID: 21197274 [TBL] [Abstract][Full Text] [Related]
22. Generation of human dendritic cells that simultaneously secrete IL-12 and have migratory capacity by adenoviral gene transfer of hCD40L in combination with IFN-gamma. Knippertz I; Hesse A; Schunder T; Kämpgen E; Brenner MK; Schuler G; Steinkasserer A; Nettelbeck DM J Immunother; 2009 Jun; 32(5):524-38. PubMed ID: 19609245 [TBL] [Abstract][Full Text] [Related]
23. A vaccine that co-targets tumor cells and cancer associated fibroblasts results in enhanced antitumor activity by inducing antigen spreading. Gottschalk S; Yu F; Ji M; Kakarla S; Song XT PLoS One; 2013; 8(12):e82658. PubMed ID: 24349329 [TBL] [Abstract][Full Text] [Related]
24. Dendritic cell internalization of α-galactosylceramide from CD8 T cells induces potent antitumor CD8 T-cell responses. Choi DH; Kim KS; Yang SH; Chung DH; Song B; Sprent J; Cho JH; Sung YC Cancer Res; 2011 Dec; 71(24):7442-51. PubMed ID: 22028323 [TBL] [Abstract][Full Text] [Related]
25. Enhancement of DNA vaccine potency by linkage of antigen gene to a gene encoding the extracellular domain of Fms-like tyrosine kinase 3-ligand. Hung CF; Hsu KF; Cheng WF; Chai CY; He L; Ling M; Wu TC Cancer Res; 2001 Feb; 61(3):1080-8. PubMed ID: 11221836 [TBL] [Abstract][Full Text] [Related]
26. Dendritic cells transduced with tumor-associated antigen gene elicit potent therapeutic antitumor immunity: comparison with immunodominant peptide-pulsed DCs. Nakamura M; Iwahashi M; Nakamori M; Ueda K; Ojima T; Naka T; Ishida K; Yamaue H Oncology; 2005; 68(2-3):163-70. PubMed ID: 16006753 [TBL] [Abstract][Full Text] [Related]
27. Priming of T cells with Ad-transduced DC followed by expansion with peptide-pulsed DC significantly enhances the induction of tumor-specific CD8+ T cells: implications for an efficient vaccination strategy. Tuettenberg A; Jonuleit H; Tüting T; Brück J; Knop J; Enk AH Gene Ther; 2003 Feb; 10(3):243-50. PubMed ID: 12571632 [TBL] [Abstract][Full Text] [Related]
28. Genetic targeting of the active transcription factor XBP1s to dendritic cells potentiates vaccine-induced prophylactic and therapeutic antitumor immunity. Tian S; Liu Z; Donahue C; Falo LD; You Z Mol Ther; 2012 Feb; 20(2):432-42. PubMed ID: 21934655 [TBL] [Abstract][Full Text] [Related]
29. IL-10 expression defines an immunosuppressive dendritic cell population induced by antitumor therapeutic vaccination. Llopiz D; Ruiz M; Infante S; Villanueva L; Silva L; Hervas-Stubbs S; Alignani D; Guruceaga E; Lasarte JJ; Sarobe P Oncotarget; 2017 Jan; 8(2):2659-2671. PubMed ID: 27926522 [TBL] [Abstract][Full Text] [Related]
30. The siRNA cocktail targeting interleukin 10 receptor and transforming growth factor-β receptor on dendritic cells potentiates tumour antigen-specific CD8(+) T cell immunity. Ahn YH; Hong SO; Kim JH; Noh KH; Song KH; Lee YH; Jeon JH; Kim DW; Seo JH; Kim TW Clin Exp Immunol; 2015 Jul; 181(1):164-78. PubMed ID: 25753156 [TBL] [Abstract][Full Text] [Related]
31. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen. Xia D; Zheng S; Zhang W; He L; Wang Q; Pan J; Zhang L; Wang J; Cao X J Mol Med (Berl); 2003 Sep; 81(9):585-96. PubMed ID: 12937899 [TBL] [Abstract][Full Text] [Related]
32. Fractalkine transgene induces T-cell-dependent antitumor immunity through chemoattraction and activation of dendritic cells. Guo J; Zhang M; Wang B; Yuan Z; Guo Z; Chen T; Yu Y; Qin Z; Cao X Int J Cancer; 2003 Jan; 103(2):212-20. PubMed ID: 12455035 [TBL] [Abstract][Full Text] [Related]
33. Polyarginine-mediated protein delivery to dendritic cells presents antigen more efficiently onto MHC class I and class II and elicits superior antitumor immunity. Mitsui H; Inozume T; Kitamura R; Shibagaki N; Shimada S J Invest Dermatol; 2006 Aug; 126(8):1804-12. PubMed ID: 16645583 [TBL] [Abstract][Full Text] [Related]
34. Successful cancer vaccine therapy for carcinoembryonic antigen (CEA)-expressing colon cancer using genetically modified dendritic cells that express CEA and T helper-type 1 cytokines in CEA transgenic mice. Ojima T; Iwahashi M; Nakamura M; Matsuda K; Nakamori M; Ueda K; Naka T; Ishida K; Primus FJ; Yamaue H Int J Cancer; 2007 Feb; 120(3):585-93. PubMed ID: 17096339 [TBL] [Abstract][Full Text] [Related]
35. Lentiviral vector-mediated autonomous differentiation of mouse bone marrow cells into immunologically potent dendritic cell vaccines. Koya RC; Kimura T; Ribas A; Rozengurt N; Lawson GW; Faure-Kumar E; Wang HJ; Herschman H; Kasahara N; Stripecke R Mol Ther; 2007 May; 15(5):971-80. PubMed ID: 17375074 [TBL] [Abstract][Full Text] [Related]
36. β-Catenin in dendritic cells exerts opposite functions in cross-priming and maintenance of CD8+ T cells through regulation of IL-10. Fu C; Liang X; Cui W; Ober-Blöbaum JL; Vazzana J; Shrikant PA; Lee KP; Clausen BE; Mellman I; Jiang A Proc Natl Acad Sci U S A; 2015 Mar; 112(9):2823-8. PubMed ID: 25730849 [TBL] [Abstract][Full Text] [Related]
37. TLR7 ligand augments GM-CSF-initiated antitumor immunity through activation of plasmacytoid dendritic cells. Narusawa M; Inoue H; Sakamoto C; Matsumura Y; Takahashi A; Inoue T; Watanabe A; Miyamoto S; Miura Y; Hijikata Y; Tanaka Y; Inoue M; Takayama K; Okazaki T; Hasegawa M; Nakanishi Y; Tani K Cancer Immunol Res; 2014 Jun; 2(6):568-80. PubMed ID: 24830413 [TBL] [Abstract][Full Text] [Related]
38. Breast cancer vaccines delivered by dendritic cell-targeted lentivectors induce potent antitumor immune responses and protect mice from mammary tumor growth. Bryson PD; Han X; Truong N; Wang P Vaccine; 2017 Oct; 35(43):5842-5849. PubMed ID: 28916248 [TBL] [Abstract][Full Text] [Related]
39. Combined Tbet and IL12 gene therapy elicits and recruits superior antitumor immunity in vivo. Qu Y; Chen L; Lowe DB; Storkus WJ; Taylor JL Mol Ther; 2012 Mar; 20(3):644-51. PubMed ID: 22215017 [TBL] [Abstract][Full Text] [Related]
40. Synergistic action of fms-like tyrosine kinase 3 ligand and CD40 ligand in the induction of dendritic cells and generation of antitumor immunity in vivo. Borges L; Miller RE; Jones J; Ariail K; Whitmore J; Fanslow W; Lynch DH J Immunol; 1999 Aug; 163(3):1289-97. PubMed ID: 10415026 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]